In vitro activity of moxifloxacin and other antimicrobials against respiratory pathogens;Actividad comparativa in vitro de moxifloxacina y otros antimicrobianos frente a patógenos respiratorios

Revista Medica de Chile

Volumn 128, Issue 12, 2000, Pages 1319-1326

  Prado J, Valeria ^a,c   Giangrieco O, Marcela ^b   Durán T, Claudia ^c   Ojeda S, Alicia ^c   Flaskamp Von F, Renate ^d  

^a UNIVERSITY OF CHILE   (Chile)

^b Alumna Prog Magister en Microbiol

^c Tecnólogo Médico ^*  (Chile)

^d Director Medico Lab Bayer de Chile   (Chile)

Author keywords

Anti infective agents; Quinolones; Respiratory tract infections

Indexed keywords

ANTIINFECTIVE AGENT; LACTAM; MACROLIDE; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MORAXELLA CATARRHALIS; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; LACTAMS; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034574357     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. GOLDSTEIN F, BRYSKIER A, APPELBAUM PC, BAUERNFEIND A, JACOBS M, SCHITO GC, WISE R. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respirarory pathogens. Clin Microbiol Infect 1998; 4: 2S8-2S18.
2. BARTLETT JG, BREINMAN RF, MANDELL LA, FILE TM JR. Community-Acquired Pneumonia in Adults: Guidelines for Management. Guidelines from the Infectious Diseases Society of America. Clin Inf Dis 1998; 26: 811-38.
3. Microbiología Médica. Segunda edición. 1997. Hartcourt Brace de España. S.A. Sección IV. Bacteriología. Patrick R. Murray. Streptococcus y bacterias gram positivas relacionadas. Cap. 20: 180-198.
4. BAQUERO F, BARRETT JF, COURVALIN P, MORROSSEY I, PIDDO L, NOVICK WJ. Epidemiology and mechanisms of resistence among respiratory tract pathogens. Clin Microbiol Infect 1998; 4: 2S19-2S26.
5. ORRANTIA GRADÍN RD, SILVA H, PONTANI DR Y EL GRUPO DE ESTUDIO ARTEMIS PARA AMÉRICA LATINA. El proyecto Artemis. Un estudio sobre la actividad de algunos antibióticos de uso común para el tratamiento de las infecciones del tracto respiratorio en diez países latinoamericanos. Rev Panamericana de Infectología 1998; 2: 68-75.
6. MACGOWAN AP, BOWKER KE, WOOTTON M, HOLT HA. The in vitro activity of Moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a phasmacodynamic model. Clin Microbiol Infect 1999; 5: 195-200.
7. LABISCHINSKI H, BAYER AG, PHARMA RESEARCH, WUPPERTAL, GERMANY. The problem of MRSA and vacomicin-resistant staphylococci. Clin Microbiol Infect 1999; 5: 3.
8. SCHMIDT FJ, KÖHRER K, SCHEURING S, VERHOEF J, FLUIT AC, HEINZ HP, JONES E. The stability of grlA, grlB, gyrA, gyrD and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 1999; 5: 287-90.
9. SIPORIN C. The evolution of fluorinated quinolones: pharmacology, microbiology, activity, clinical uses and toxicities. Ann Rev Microbiol 1989; 43: 601-27.
10. CASELLAS JM. Pasado presente y futuro de las quinolonas. Punto de vista microbiológico. Rev Argentina de Infectología. 1997; X: 3-10.
11. PIDDOCK LJ. New quinolones and Grain-positive bacteria. Antimicrob 1994; 38: 163-9.
12. RUBINSTEIN E, CARBON C, RANGARAJ M, SANTOS JI, THYS J-P, VEYSSIER P. Lower respiratory tract infections: etiology, current treatment and experience with fluoroquinolones. Clin Microbiol Infect 1998; 4: 2S42-2S50.
13. WIEDEMANN B, PFEIL E, WIEGAND I. Comparative pharmodynamic activity of Grepafloxacin and macrolides in an in vitro model against respiratory tract pathogens. Clin Microbiol Infect 1999; 5: 293.
14. ELIES W, VOGEL F, LODE H. Efficacy and tolerability of grepafloxacin: results of a German surveillance study in 9398 patients. Clin Microbiol Infect 1999; 5: 145.
15. WIEDEMANN B. What antibacterial characteristics are required for an antibiotic used for the treatment of community-acquired lower respiratory tract infections?. Clin Microbiol Infect 1999; 5: 4.
16. DALHOFF A. Antimicrobial espectrum of moxifloxacin. Clin Microbiol Infect 1999; 5: 39.
17. SPRINGSKLEE M, REITER C, MEYER JM. Safety and tolerability profile of moxifloxacin. Clin Microbiol Infect 1999; 5: 140.
18. BLONEAU JM, BROWN EM, WOOD MJ (EDS.) Moxifloxacin: a new respiratory quinolone. J Antimicrob Chemother 1999; 43 (suppl): 1-100.
19. MACGOWAN AP. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Exp Opin Invest Drugs 1999; 8: 181-99.
20. BAKER CN, STOCKER SA, CULVER DH, THORNSBERRY C. Comparison of the E-test to agar dilution, broth dilution and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29: 533-8.
21. JORGENSEN JH, HOWELL AW, MAHER LA. Quantitative antimicrobial susceptibility testing to Haemophilus influenzae and Streptococcus pneumoniae by using the E-test. J Clin Microbiol 1991; 29: 109-14.
22. ANHALT JP, SABATH LD, BARRY AL. Special tests: bactericidal activity, activity of antimicrobics in combination, and detection of betalactamase production. En Lennette EJ, Ballows A, Hausler WJ, Shadomy HJ, (eds). Manual of Clinical Microbiology 3th ed, Washington DC, ASM 1980; 478-84.
23. WARD J. Antibiotic-resistant Streptococcus pneumoniae: Clinical and epidemiological aspects. Rev Infect Dis 1981; 3: 254-65.
24. BARRY B, MUFFAT-JOLY M, GEHANNO P, POCIDALO JJ. Effect of increased dosages of amoxicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1993; 37: 1599-603.
25. KENT H, RICCI V, PIDDOK LJV. Characterization of mutant fluoroquinolone resistant S pneumoniae selected with ciprofloxacin or moxifloxacin. Clin Microbiol Infect 1999; 53: 296.
26. SCHMIDT F-J, HOFMANN B, HANSEN B, SCHEURING S, LUCKEFAHR M, KLOOTWIJK M, ET AL. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin MICs and mutations in grlA, gyrA and gyrB in 116 unrelated clinical isolates of S aureus. Antimicrob Chemother 1998; 41: 481-4.